Interventions for Hidradenitis Suppurativa Updated Summary of an Original Cochrane Review

被引：15

作者：

Ingram, John R. ^{[1
]}

机构：

[1] Cardiff Univ, Dept Dermatol & Acad Wound Healing, Inst Infect & Immun, Cardiff, S Glam, Wales

来源：

JAMA DERMATOLOGY | 2017年 / 153卷 / 05期

关键词：

RANDOMIZED-TRIAL; ADALIMUMAB;

D O I：

10.1001/jamadermatol.2017.0432

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

CLINICAL QUESTION Which treatments have been shown to be effective in randomized clinical trials (RCTs) for hidradenitis suppurativa (HS) in adults? BOTTOM LINE There is high-quality evidence of benefit from adalimumab given weekly, while every other week dosing is ineffective, with reductions in Dermatology Life Quality Index (DLQI) scores compared with placebo of 2.8 points (95% CI, -3.7 to -2.0 points) and 1.6 points (95% CI, -3.9 to 0.6 points), respectively. Moderate-quality evidence suggests that infliximab is beneficial; RCT evidence for other interventions was lower in quality or absent, limiting further conclusions.

引用

页码：458 / 459

页数：2

共 9 条

[1] Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatogy Life Quality Index (DLQI): Further Data
Basra, M. K. A.
Salek, M. S.
Camilleri, L.
Sturkey, R.
Finlay, A. Y.
[J]. DERMATOLOGY, 2015, 230 (01) : 27 - 33
[2] Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process
Ingram, J. R.
Hadjieconomou, S.
Piguet, V.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (02) : 263 - 272
[3] Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality
Ingram, J. R.
Woo, P. N.
Chua, S. L.
Ormerod, A. D.
Desai, N.
Kai, A. C.
Hood, K.
Burton, T.
Kerdel, F.
Garner, S. E.
Piguet, V.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (05) : 970 - 978
[4] The Hidradenitis Suppurativa Priority Setting Partnership
Ingram, J. R.
Abbott, R.
Ghazavi, M.
Alexandroff, A. B.
McPhee, M.
Burton, T.
Clarke, T.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : 1422 - 1427
[5] Interventions for hidradenitis suppurativa
Ingram, John R.
Woo, Pick-Ngor
Chua, Ser Ling
Ormerod, Anthony D.
Desai, Nemesha
Kai, Anneke C.
Hood, Kerry
Burton, Tara
Kerdel, Francisco
Garner, Sarah E.
Piguet, Vincent
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (10):
[6] Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Kimball, Alexa B.
Okun, Martin M.
Williams, David A.
Gottlieb, Alice B.
Papp, Kim A.
Zouboulis, Christos C.
Armstrong, April W.
Kerdel, Francisco
Gold, Michael H.
Forman, Seth B.
Korman, Neil J.
Giamarellos-Bourboulis, Evangelos J.
Crowley, Jeffrey J.
Lynde, Charles
Reguiai, Ziad
Prens, Errol-Prospero
Alwawi, Eihab
Mostafa, Nael M.
Pinsky, Brett
Sundaram, Murali
Gu, Yihua
Carlson, Dawn M.
Jemec, Gregor B. E.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (05) : 422 - 434
[7] Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa A Parallel Randomized Trial
Kimball, Alexa B.
Kerdel, Francisco
Adams, David
Mrowietz, Ulrich
Gelfand, Joel M.
Gniadecki, Robert
Prens, Errol P.
Schlessinger, Joel
Zouboulis, Christos C.
van der Zee, Hessel H.
Rosenfeld, Marie
Mulani, Parvez
Gu, Yihua
Paulson, Susan
Okun, Martin
Jemec, Gregor B. E.
[J]. ANNALS OF INTERNAL MEDICINE, 2012, 157 (12) : 846 - +
[8] A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
Miller, I.
Lynggaard, C. D.
Lophaven, S.
Zachariae, C.
Dufour, D. N.
Jemec, G. B. E.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (02) : 391 - 398
[9] European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Zouboulis, C. C.
Desai, N.
Emtestam, L.
Hunger, R. E.
Ioannides, D.
Juhasz, I.
Lapins, J.
Matusiak, L.
Prens, E. P.
Revuz, J.
Schneider-Burrus, S.
Szepietowski, J. C.
van der Zee, H. H.
Jemec, G. B. E.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (04) : 619 - 644

← 1 →